---
title: Microalbuminuria and Allopurinol in Type 1 Diabetes
nct_id: NCT02829177
overall_status: COMPLETED
phase: PHASE4
sponsor: Peter Rossing
study_type: INTERVENTIONAL
primary_condition: Type 1 Diabetes
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02829177.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02829177"
ct_last_update_post_date: 2018-09-10
last_seen_at: "2026-05-12T06:28:00.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Microalbuminuria and Allopurinol in Type 1 Diabetes

**Official Title:** A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria

**NCT ID:** [NCT02829177](https://clinicaltrials.gov/study/NCT02829177)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Peter Rossing
- **Conditions:** Type 1 Diabetes, Diabetic Nephropathy
- **Start Date:** 2014-09
- **Completion Date:** 2017-09-20
- **CT.gov Last Update:** 2018-09-10

## Brief Summary

The objective is to determine if lowering serum uric acid by means of allopurinol in the course of kidney disease may be effective in preventing or improving albuminuria and renal function in Type 1 Diabetic patients. The study is a double blinded, randomised, placebo-controlled cross-over clinical trial.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Albuminuria (≥30 mg/g)
* Uric Acid ≥ 0,265 mmol/l
* GFR (glomerular filtration rate) \> 40 ml/min/1.73m2

Exclusion Criteria:

* History of gout or xanthinuria or other indications for uric acid lowering therapy such as cancer chemotherapy.
* Recurrent renal calculi.
* Current use of azathioprine, 6-mercaptopurine, didanosine, tamoxifen, amoxicillin/ampicillin, or other drugs interacting with allopurinol.
* Known allergy to xanthine-oxidase inhibitors.
* Renal transplant.
* Non-diabetic kidney disease.
* Home, 24h og clinical BP\>180 or Diastolic BP \>130 mmHg at screening.
* Cancer treatment within two years before screening.
* History of hepatitis B or C.
* History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV) infection.
* History of alcohol or drug abuse.
* Breastfeeding or pregnancy or unwillingness to be on contraception throughout the trial.
* Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study.
* Serious pre-existing medical problems other than diabetes, e.g. congestive heart failure, pulmonary insufficiency.
```

## Arms

- **Allopurinol** (ACTIVE_COMPARATOR) — 400 mg once daily, tablet treatment
- **Placebo** (PLACEBO_COMPARATOR) — Identical tablet treatment

## Interventions

- **Allopurinol** (DRUG)
- **Placebo** (DRUG)

## Primary Outcomes

- **Improved Albuminuria** _(time frame: 60 days)_ — Improvement of albuminuria will be evaluated by the collection of 24h urin collection with the measure of 24h albumine excretion rate and the measurements will be compared for the two treatment arm for each participant.

## Locations (1)

- Steno Diabetes Center, Gentofte Municipality, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.steno diabetes center|gentofte municipality||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02829177.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02829177*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*